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AbstrACt
Objective International differences in colorectal cancer 
(CRC) survival and stage at diagnosis have been reported 
previously. They may be linked to differences in time 
intervals and routes to diagnosis. The International Cancer 
Benchmarking Partnership Module 4 (ICBP M4) reports the 
first international comparison of routes to diagnosis for 
patients with CRC and the time intervals from symptom 
onset until the start of treatment. Data came from patients 
in 10 jurisdictions across six countries (Canada, the UK, 
Norway, Sweden, Denmark and Australia).
Design Patients with CRC were identified via cancer 
registries. Data on symptomatic and screened patients 
were collected; questionnaire data from patients’ primary 
care physicians and specialists, as well as information 
from treatment records or databases, supplemented 
patient data from the questionnaires. Routes to diagnosis 
and the key time intervals were described, as were 
between-jurisdiction differences in time intervals, using 
quantile regression.
Participants A total of 14 664 eligible patients with CRC 
diagnosed between 2013 and 2015 were identified, of 
which 2866 were included in the analyses.
Primary and secondary outcome measures Interval 
lengths in days (primary), reported patient symptoms 
(secondary).
results The main route to diagnosis for patients was 
symptomatic presentation and the most commonly 
reported symptom was ‘bleeding/blood in stool’. The 
median intervals between jurisdictions ranged from: 21 
to 49 days (patient); 0 to 12 days (primary care); 27 to 
76 days (diagnostic); and 77 to 168 days (total, from first 
symptom to treatment start). Including screen-detected 
cases did not significantly alter the overall results.
Conclusion ICBP M4 demonstrates important differences 
in time intervals between 10 jurisdictions internationally. 
The differences may justify efforts to reduce intervals in 
some jurisdictions.
bACkgrOunD 
Colorectal cancer (CRC) is a leading cause 
of morbidity and mortality and places a 
major burden on health systems; worldwide 
strengths and limitations of this study
 ► This is the first international study of this scale to 
use standardised survey methods to systematical-
ly examine key intervals from patients first noticing 
symptoms or bodily changes until the start of treat-
ment for their colorectal cancer.
 ► Questionnaire data were enriched and validated 
with registry data (cancer registry and screening 
programmes) and data rules were applied consis-
tently to ensure validity.
 ► As with all questionnaire based studies, there may 
be some response differences due to participant 
interpretation, cohort characteristics and sampling 
strategy, but we did not find obvious differences 
between study participants which could bias our 
results.
 ► While our analyses adjusted for age, gender and co-
morbidity, we were unable to adjust for ethnicity and 
education due to different classification systems in 
participating countries.
 ► Understanding variations in diagnostic and treat-
ment intervals for patients with colorectal cancer 
may, in jurisdictions with longer intervals, signal the 
need for improvements in service configuration and 
patient pathways.
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1.36 million new cases are diagnosed every year.1 CRC is 
the second most common cause of death due to cancer 
in Europe after female breast cancer, accounting for 
more than 200 000 deaths per year.2 Prognosis strongly 
depends on stage at diagnosis, and the disease can 
mostly be cured if diagnosed at an early stage. Survival 
has increased over the last several years in Europe.3 
However, there remains substantial international vari-
ation in both 1-year and 5-year survival, with countries 
such as the UK and Denmark having significantly poorer 
survival than other countries such as Sweden, Canada 
and Australia (figure 1).4 Some of the variation derives 
from differences in stage at diagnosis which, in turn, 
is a result of the pathway to diagnosis and treatment.5 
Figure 1 Survival differences for colorectal cancer demonstrated in the International Cancer Benchmarking Partnership 
Module 1.4
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Therefore, it is crucial to investigate international 
differences in this pathway for CRC.
The International Cancer Benchmarking Partnership 
(ICBP) aims to not only quantify survival differences in 
comparable countries but to explore factors which may 
impact on observed differences.6 Module 4 (ICBP M4) 
focusses on the routes to diagnosis and length of diag-
nostic and treatment intervals as a means of under-
standing differences in cancer prognosis between 
countries. This may help shape policy and practice inter-
ventions in participating jurisdictions.6
Diagnosis of CRC can be difficult; the symptoms are 
often vague (eg, fatigue and non-specific abdominal 
pain), and this poses a significant diagnostic challenge for 
primary care, where most patients with CRC present.7–12 
There is growing evidence that prolonged diagnostic and 
treatment intervals are associated with poorer outcomes 
in CRC.13 14 Access to investigations such as flexible 
sigmoidoscopy and colonoscopy is a further key issue; 
open access may expedite diagnosis and effect short diag-
nostic intervals.12 15
Many countries have implemented screening—typically 
faecal occult blood test (FOBT)-based—which can make 
a significant contribution to improved CRC outcomes.16 
However, currently, the large majority of CRC diagnoses 
are based on symptomatic presentation—for example, 
seeking help in primary care or attending emergency 
services.7 17
This study aims to systematically compare the diagnostic 
routes and time intervals from first noticing symptoms to 
start of treatment in patients with CRC in 10 healthcare 
systems with broadly similar access to high quality treat-
ment and valid cancer registration.6
MethODs
The methods for ICBP M4 have been described.18 In 
brief, we recruited patients through cancer registries 
in 10 jurisdictions: Victoria (Australia); Manitoba and 
Ontario (Canada); Denmark; Norway; Sweden; England, 
Scotland, Northern Ireland and Wales (the UK). The 
target was to recruit 200 symptomatic recently diagnosed 
patients with CRC per jurisdiction and to measure the 
patient, primary care, diagnostic, treatment and total 
intervals (figure 2).
In defining these intervals we used principles artic-
ulated in the Aarhus Statement.19 Data were collected 
from patients, their primary care physician (PCP) and 
their cancer treatment specialists (CTSs) as well as cancer 
registries. When calculating the route and time intervals 
we used predefined rules including a data ‘hierarchy’ 
around these information sources (online supplementary 
file 1). Based on a standardised protocol, teams within 
each jurisdiction established data collection processes 
with registries; survey logistics and data management 
were adapted to each local setting.
Data were transferred in anonymised format to the 
analysis team at Aarhus University—all data sources were 
combined into a single database.
Figure 2 Diagnosis and treatment of colorectal cancer: illustration of key time points and intervals.19 PCP, primary care 
physician.
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Identification of study population
Eligible patients were consecutive patients aged 40 years 
or more with a first-diagnosis of CRC, International Classi-
fication of Diseases (ICD) 10 coded as C18.0-C18.9, C20.0 
and C20.9.20 Patients who had had another non-index 
cancer earlier were eligible, but those with synchronous 
different primary cancers were excluded.18
Each jurisdiction used a registry-based identification to 
enhance validity. We aimed to recruit patients 3–6 months 
after diagnosis; this avoided approaching patients too 
soon after diagnosis, while minimising recall bias from a 
long period post-diagnosis.
Recruitment was via cancer registries; either through 
(1) sending a letter to the relevant healthcare profes-
sional, requesting a preaddressed envelope be forwarded 
to the patient on confirmation the person was aware of 
the diagnosis or (2) the local research team or registry 
directly sending a letter to the patient.18 Consent was 
required from all patients prior to surveys being sent to 
PCPs and CTSs and for data transfer.
Data sources
Data from three questionnaires of eligible patients, their 
PCPs and CTSs (online supplementary files 2-4) were 
combined with information from participating cancer 
registries. Development, validation and implementation 
of these surveys is explained elsewhere.18
Survey data
Questionnaires were developed collaboratively with all 
jurisdictions. For consented patients, based on practice 
lists or the patient’s response, a questionnaire was sent 
to the PCP with whom they were listed or who had been 
primarily involved in the diagnostic pathway. The patients 
and PCPs were asked about milestones, symptoms and 
route to cancer diagnosis. A questionnaire was sent to 
the CTSs who were first involved in the treatment. Juris-
dictional differences in local recruitment processes are 
detailed in online supplementary files 5.
Registry data
To enhance complete and valid data on date of diagnosis, 
stage and screening status, data were collected through 
cancer registries wherever possible. Date of diagnosis was 
defined based on an established International Agency 
for Research on Cancer (IARC) hierarchy and stage was 
preferably given in tumour, node and metastasis and 
Duke’s.21 22
Data handling
Local teams entered data and questionnaire responses. 
The records were checked for obvious errors (eg, dates 
in future) and queries were discussed and resolved with 
local contacts, who checked responses against original 
survey. All survey data underwent cleaning centrally 
(Aarhus University) to ensure that the same explicit rules 
were applied on the full dataset. Patients where age, 
date of diagnosis or date of consent were unknown were 
excluded.
As described, the data rules allowed the combination 
of data from different sources in a standardised way that 
ensured reproducibility and transparency (online supple-
mentary files 1). The rules, based on the Aarhus State-
ment,19 employed a ‘hierarchy’ principle in terms of the 
order in which data sources (patient, PCP, CTS, registry) 
should take precedence where responses between sources 
differed, and included imputation rules based on the 
available data. The exact rule was guided by the measure 
in question—for example, patient interval was collected 
primarily from the patient questionnaire whereas primary 
care time-points were collected from the PCP question-
naire. All the measures were further validated using 
algorithms for outliers and out of range responses (eg, 
negative time intervals).
Although the protocol mandated contacting patients 
within a 3–6-month time window after diagnosis, some 
local registries needed to extend this period, primarily 
due to delays in recording the cancer diagnosis.
Measures of routes to diagnosis
We defined routes to diagnosis for CRC using catego-
ries derived from the Aarhus Statement check-list—the 
following categories were used in the analysis19:
 ► Screening.
 ► Symptomatic:
 –  Visit PCP.
 –  Visit PCP and accident and emergency (A&E).
 –  A&E.
 –  Investigation for another problem.
 ► Other/unknown routes to diagnosis.
Measures of time intervals
To ensure international comparison, the time interval 
definition was adapted from the Aarhus Statement and 
included the following time-points19:
 ► First onset of symptoms: the time-point when first 
bodily change(s) and/or symptom(s) are noticed by 
the patient.
 ► First presentation to healthcare: the time-point at 
which it would be at least possible for the clinician 
seeing the patient to have started investigating.
 ► First referral to secondary care: the time-point at 
which the PCP refers the patient (and responsibility 
of the patient) to secondary/specialist care.
 ► Date of diagnosis: date the definite diagnosis was 
made, defined by the IARC hierarchy.21
 ► Date of start of treatment: the date where the patient 
started curative or palliative treatment or a decision 
not to treat.
The time intervals were calculated as the number of 
days between these time-points (figure 2). For screen 
detected CRC, the patient and primary care interval 
were not applicable, with other intervals calculated 
using screening date as the first time-point. All time-
points were validated manually and negative intervals 
were set to 0 days. Missing day was imputed based on 
specific rules to ensure that the direction of a possible 
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misclassification bias was known (online supplementary 
files 1).
establishing screening status
Patients with CRC were categorised using data rules as 
‘screen-detected’, ‘symptomatic’ or ‘other presentation’. 
In some jurisdictions it was possible to identify screen-de-
tected cancers from registries; in others this categorisation 
depended on questionnaire responses. Due to differ-
ences in the understanding and registration of screening 
across jurisdictions, we specified symptom-based detec-
tion should include all patients who reported symptoms 
or A&E/primary care presentation, even if the patient 
had indicated ‘screening’ as the diagnostic route (unless 
their PCP or CTS specified a screening route). For UK 
countries the distinction between a screen-detected and 
non-screen-detected CRC was validated using registry 
data on screen-detected cases identified through public 
programmes.
Covariates
Health status was measured using the self-reported 
general health item from the 36-Item Short Form Health 
Survey.23 Comorbidity was assessed from the patient 
survey as presence of four diseases (stroke, diabetes, lung 
or heart diseases) and categorised into: ‘none’, ‘medium’ 
(one or two) or ‘high’ (three or four). Educational level 
was categorised as ‘low’ (vocational school or lower) and 
‘high’ (university or higher). Symptoms reported were 
divided into two categories: ‘a CRC specific symptom’ or 
‘other symptoms’. This was based on a symptom coding 
done independently by two PCP-authors (DW and PV) 
with the aim of identifying symptoms where clinical suspi-
cion could be raised.24
statistical analysis
Quantile regression was used to estimate differences in 
intervals between all jurisdictions.25 We compared the 
50th, 75th and 90th percentiles. Wales was used as the 
reference jurisdiction as it had the lowest CRC survival 
according to the ICBP Module 1 cancer survival bench-
mark.4 Quantile regression allows a comparison on the 
interval scale with optimal information on differences. 
Counting days, we used the ‘qcount’ procedure proposed 
by Miranda.26 Parameters were calculated with 1000 
jittered samples. The differences (in days) in intervals 
between jurisdictions (using Wales as a reference) were 
calculated as marginal effects after quantile regression 
by setting the continuous covariate age to its mean value 
and the categorical covariates (gender and comorbidity) 
to their modes. Significance level was set to 0.05 or less, 
and 95% CI were calculated when appropriate. Statistical 
analyses were carried out using STATA V.14 software.
sensitivity and validity analyses
All analyses were undertaken using the 6 and 9 months 
cut-off criteria for allowable interval from diagnosis to 
questionnaire completion. To estimate the effect of 
using patient reported intervals only, a sensitivity analysis 
based solely on patient data was performed. The effect 
of excluding patients for whom at least one time interval 
hadn’t been reported was also investigated.
Kappa coefficient and overall agreement percentage 
assessed the agreement on routes to diagnosis (screening 
and symptomatic presentation) between the different 
data sources. Kappa coefficients were interpreted using 
Landis’ and Koch’s criteria27: 0.00–0.20=slight, 0.21–
0.40=fair, 0.41–0.60=moderate, 0.61–0.80=substantial, 
above 0.80=almost perfect.
Agreement between the different data sources was also 
assessed by Lin’s concordance correlation coefficient 
(CCC).28 The ICBP M4 definition of screening-status 
was validated against registry data on screening where 
available, and assessed by kappa and overall agreement 
percentage.
Patient involvement
The research questions for this survey drew on an exten-
sive literature elating diagnosis and treatment delays 
leading to negative patient experiences. While patient 
experience was not a primary outcome measure for this 
study, patients were given the opportunity to comment 
on their experience through questionnaire free-text 
response options (under separate analysis). Patients were 
involved in the piloting of study instruments to ascertain 
if recruitment and questionnaire content and dissemina-
tion strategies were appropriate, described elsewhere.18 
Each jurisdiction has committed to communicating the 
findings and local implications of this study to organisa-
tions representing their study participants.
results
Patient characteristics and participation
Of 14 664 eligible patients, 3881 returned completed 
questionnaires (a 31% response rate, ranging from 19% 
in Norway to 69% in Denmark). Of these, 2866 (95%) 
were included in the analyses after application of inclu-
sion and exclusion criteria. The study flow with identifica-
tion, exclusion and responses for each jurisdiction is seen 
in table 1.
The characteristics of the included patients are detailed 
in table 2. The patient questionnaire was completed at 
a median of 5 months following diagnosis. For tumour 
stage the proportion of missing stage was high in Norway 
due to lack of registry data.
routes to diagnosis
Routes to diagnosis were broadly similar, except for 
screening; of all patients, 16.1% had a screen detected 
CRC, ranging from 6.3% in Norway to 31.4% in Manitoba 
(table 3). In Denmark and Sweden CRC-screening had 
not been implemented at the time of study and screening 
status in Norway was determined by information from 
local screening trials. The proportion of screen-de-
tected cancers in Northern Ireland is lower as most were 
excluded in the recruitment process, with the local team 
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actively including symptomatic patients in order to reach 
the target of 200 symptomatic patients. Overall (excluding 
Northern Ireland), most (82.2%) respondents presented 
with a symptomatic CRC. A high level of agreement was 
found between ICBP and registry data for screening 
status (table 3). PCP data indicated that the percentage of 
the symptomatic patients urgently referred with a suspi-
cion of cancer was less than 50% in Ontario, Denmark, 
Manitoba, Norway (37.8%, 39.6%, 46.8%, 47.8%, corre-
spondingly) and larger than 50% in Scotland, Northern 
Ireland, Victoria, England, Wales (51.5%, 57.1%, 57.6%, 
67.6%, 69.3%, correspondingly).
symptom prompting concern
The proportion (%) of patients and PCPs reporting 
symptoms are shown in table 4 (for Northern Ireland 
and Sweden, only patient data were collected). The 
most common symptom reported by PCP respondents 
was rectal bleeding (40% of respondents), followed by 
change in bowel habit. While every third patient indi-
cated fatigue as a key symptom, it was rarely reported by 
PCPs.
time intervals
The median patient interval varied from 21 days 
(Denmark) to 49 days (Wales) (table 5). Table 6 shows 
the adjusted patient median interval was 25 days shorter 
in Denmark than in Wales; none were longer compared 
with Wales (online supplementary files 6).
The median primary care interval was 12 days in Norway 
(table 5), statistically significantly longer than Wales 
(table 6). For the 10% of patients waiting longest for 
referral, the longest intervals were observed in Manitoba, 
Victoria and Scotland (210, 128 and 93 days, respectively) 
(table 5). This interval at the 90th percentile was either 4 
months (Manitoba) or 1 month (Victoria and Scotland) 
longer than in Wales (table 6).
The median diagnostic interval for symptomatic patients 
ranged from 27 to 28 days in Denmark and Victoria to 76 
days in Manitoba. At the 90th percentile it ranged from 
4 months in Denmark to 10 months in Ontario (table 5). 
All jurisdictions had shorter median diagnostic inter-
vals compared with Wales, except Northern Ireland and 
Manitoba, where the intervals were 5 and 14 days longer, 
respectively (table 6).
The shortest median treatment intervals for all patients 
(about 2 weeks) were observed in Denmark, Victoria and 
Norway. In other jurisdictions this interval was 1 month 
or more (table 5). All jurisdictions had shorter treatment 
intervals compared with Wales, except Scotland and 
Manitoba (table 6).
The median total interval (from first symptom to treat-
ment start) for all patients with CRC was between 74 days 
(Victoria) and 136 days (Manitoba) (table 5). In Scot-
land, Denmark, Norway and Victoria, this interval was 
statistically significantly shorter than in Wales (table 6).J
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Table 5 The time intervals (days) for each of the 10 jurisdictions depicted as median, 75th and 90th percentiles
Wales England Scotland
Northern 
Ireland Denmark Manitoba Norway Sweden Ontario Victoria
Patient interval
(Symptomatic 
patients)
Number (n=195) (n=199) (n=175) (n=199) (n=292) (n=134) (n=240) (n=266) (n=230) (n=199)
Median 49 34 30 35 21 34 36 31 31 22
75th 
percentile
92 118 73 88 62 92 92 92 96 63
90th 
percentile
249 346 181 312 180 215 218 201 304 234
Primary care 
interval
(Symptomatic 
patients)
Number (n=157) (n=152) (n=127) (n=160) (n=207) (n=72) (n=124) (n=0) (n=77) (n=117)
Median 3 2 4 0 1 4 12 n/a 1 9
75th 
percentile
20 21 28 14 10 30 39 n/a 23 32
90th 
percentile
78 54 93 54 51 210 82 n/a 70 128
Diagnostic 
interval
(Symptomatic 
patients)
Number (n=194) (n=196) (n=174) (n=190) (n=290) (n=133) (n=229) (n=249) (n=218) (n=197)
Median 60 48 38 64 27 76 37 36 54 28
75th 
percentile
155 86 91 111 66 162 85 82 146 66
90th 
percentile
284 201 164 238 129 365 222 196 312 200
Diagnostic 
interval
(Screen-
detected 
patients)
Number (n=69) (n=56) (n=76) (n=35) (n=0) (n=25) (n=14) (n=0) (n=50) (n=38)
Median 35 25 36 0 n/a 66 22 n/a 3 40
75th 
percentile
65 46 49 0 n/a 111 48 n/a 43 64
90th 
percentile
99 70 76 0 n/a 206 84 n/a 120 122
Diagnostic 
interval
(All patients)
Number (n=263) (n=252) (n=250) (n=225) (n=290) (n=158) (n=243) (n=249) (n=268) (n=235)
Median 52 43 37 47 27 72 36 36 44 28
75th 
percentile
120 76 72 101 66 139 85 82 128 64
90th 
percentile
242 176 151 207 129 320 212 196 278 178
Treatment 
interval
(Symptomatic 
patients)
Number (n=197) (n=206) (n=185) (n=208) (n=306) (n=161) (n=258) (n=281) (n=248) (n=209)
Median 39 31 33 25 14 34 18 35 33 14
75th 
percentile
59 47 56 40 19 59 29 52 54 29
90th 
percentile
83 60 79 58 28 97 45 65 79 47
Treatment 
interval
(Screen-
detected 
patients)
Number (n=72) (n=58) (n=78) (n=34) (n=0) (n=79) (n=17) (n=0) (n=52) (n=60)
Median 44 39 49 38 n/a 38 19 n/a 40 17
75th 
percentile
68 46 71 52 n/a 61 27 n/a 54 35
90th 
percentile
80 62 91 61 n/a 83 43 n/a 88 44
Treatment 
interval
(All patients)
Number (n=271) (n=268) (n=266) (n=246) (n=312) (n=240) (n=279) (n=284) (n=310) (n=276)
Median 41 34 37 27 14 35 18 36 34 15
75th 
percentile
63 47 63 42 19 60 28 53 54 29
90th 
percentile
80 61 87 59 27 88 43 65 82 44
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sensitivity and validity analyses
Changing the cut-off survey completion date from 9 
months post-diagnosis to the per-protocol 6 months 
changed the number of included patients. However, the 
estimates of routes to diagnosis and time intervals were 
not significantly altered and the trend was the same as in 
the main analyses (results not shown). Sensitivity analysis 
based solely on patient data for those whose reporting 
on all time intervals was complete did not change the 
trend (results not shown). Comparing patient and PCP 
reported routes (screening and symptomatic presenta-
tion) and registry data on screening showed that agree-
ment ranged from moderate to almost perfect (kappa 
0.59–0.86).
Comparing the dates between the different data sources 
showed a high agreement between all data sources for 
all categories of dates (CCC ≥ 0.95 for date of diagnosis, 
CCC=0.94 for date of treatment and CCC=0.92 for date 
of first presentation to primary care). The analysis of 
the ICBP M4 definition of screening route compared 
with registry data showed an almost perfect agree-
ment (kappa >0.80) in two jurisdictions and substantial 
(kappa >0.70) in two jurisdictions (table 3).
DIsCussIOn
Our study showed marked variation in the proportion of 
screen-detected cancers, lengths of diagnostic and treat-
ment (and total) intervals between jurisdictions. Patient 
intervals were shortest in Denmark and longest in Wales; 
longer primary care intervals were present in Norway, 
Scotland, Manitoba and Victoria. Differences in primary 
care intervals do not necessarily reflect PCP delay—they 
may arise from PCPs undertaking more investigations 
prior to referral. Overall, the differences are marked and 
suggest the need, in some jurisdictions, for revised diag-
nostic pathways to reduce the time taken for patients to 
be diagnosed and treated.
The interval differences did not show an obvious asso-
ciation with earlier reported survival differences—juris-
dictions with poorer survival did not consistently show 
longer intervals, and vice versa.4 While this may ques-
tion the validity of our findings, and/or the relationship 
between diagnostic intervals and survival, it is important 
to note these analyses were several years apart, and there 
may have been significant health system changes since 
the survival comparisons. Nevertheless, our study adds to 
a growing body of evidence on routes to diagnosis and 
time intervals; there are few similar examples involving 
multiple countries in the literature.29
Many factors underpin the differences observed between 
jurisdictions, such as structural differences in healthcare 
delivery (eg, care pathways, availability and accessibility 
of diagnostic and treatment facilities, etc.). Differences 
in routes to diagnosis were influenced by the presence 
or absence of screening programmes (CRC-screening 
had not been implemented in Denmark and Sweden at 
the time of study). Patient interval variation may reflect 
differences in symptom awareness or health-seeking 
behaviour. However, a study which compared awareness 
of cancer symptoms, attitudes towards cancer and barriers 
to attending a PCP did not demonstrate statistically signif-
icant differences.30 It is possible that other factors, such as 
culture, rurality, economic or patient-specific barriers and 
facilitators, influence this important part of the pathway.31
There were significant differences in primary care 
intervals; overall these intervals were much longer than 
those found in our breast cancer analyses.32 This raises 
important questions about diagnostic processes within 
primary care. There are widespread calls for PCPs to play 
a greater role in improving outcomes in CRC.33 Indeed, 
it is now widely acknowledged that primary care has a 
major role in cancer control at all stages of the patient 
journey.34 Nevertheless, there is some evidence based 
on observational associations that prolonged intervals 
might be associated with stronger ‘gatekeeper’ systems.35 
Wales England Scotland
Northern 
Ireland Denmark Manitoba Norway Sweden Ontario Victoria
Total interval
(Symptomatic 
patients)
Number (n=154) (n=165) (n=147) (n=175) (n=249) (n=123) (n=210) (n=238) (n=214) (n=168)
Median 168 145 120 138 77 154 108 127 124 90
75th 
percentile
304 248 184 235 146 307 203 224 251 182
90th 
percentile
365 365 326 365 248 365 312 365 365 357
Total interval
(All patients)
Number (n=222) (n=221) (n=223) (n=209) (n=249) (n=148) (n=224) (n=238) (n=262) (n=205)
Median 128 112 103 111 77 136 102 127 105 74
75th 
percentile
239 201 159 211 146 266 194 224 230 153
90th 
percentile
365 365 253 365 248 365 307 365 365 320
In Sweden, no data on the primary care interval was available.
Table 5 Continued 
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Further, independent of the nature of symptoms, inves-
tigation in primary care has been noted to be associated 
with later referral for specialist assessment for CRC and 
other cancers—so a long primary care interval may mean 
that PCPs are doing more before they refer.36 Hence, 
PCP access to and use of investigations and differing 
national cancer referral guidance may influence primary 
care intervals. There were differences in diagnostic inter-
vals, suggesting that once patients have been referred to 
secondary care there is considerable variation in their 
experiences; differences in treatment intervals were 
less marked. These variations suggest there is room 
for improvement in reducing the total interval and its 
various subintervals, and that guidance on optimal path-
ways should be better implemented. Each participating 
jurisdiction will likely draw unique conclusions about the 
most appropriate response to our findings.
strengths and weaknesses
A major strength of this study is its use of standardised 
survey methods in a broad range of jurisdictions to 
systematically examine the various components of these 
intervals and to describe and compare, between coun-
tries, patient journeys to a cancer diagnosis and treat-
ment. To ensure comparability across jurisdictions, our 
surveys drew on existing instruments and went through 
an extensive process of cognitive testing, piloting, and 
translation and adaptation.18
Data quality was enriched by information from national 
cancer registries and our algorithms showed very good 
agreement for jurisdictions where validation was possible. 
Using validated identification of patients with CRC mini-
mised the risk of missing cancer cases during inclusion 
and of selection bias. Further, the use of registries made 
it possible to exclude patients with previous cancer in the 
same site, providing a homogeneous group of newly diag-
nosed patients with CRC in need of diagnostic work-up.
It was evident that there were subtle differences in 
the understanding of ‘screening’ between jurisdic-
tions. Patients do not always distinguish between tests 
for screening and those for symptom-based diagnosis. 
Including data from registries and triangulating patient 
and PCP data enhanced the validity of ‘screen-detected 
versus non-screen-detected’ information, but the under-
lying factors varied between jurisdictions—for example, 
in Australia PCPs often provide screening FOBTs during 
consultations whereas this is rare in the UK and Scandi-
navia. To counter these inconsistencies, we applied our 
validated data rules which showed a high agreement with 
screening registries.
There are inevitable differences in questionnaire inter-
pretation, characteristics of non-responders and avail-
ability of supplementary data for validation purposes. 
There are always considerations with questionnaire 
interpretation but the methodology and analysis of 
data sought to minimise or account for this as much as 
possible. Further, we used triangulation and compre-
hensive data rules to ensure validity, consistency and 
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preserve statistical precision.18 We included registry data 
where possible (screening, stage, date of diagnosis) and 
developed reliable rules for imputation based on these 
registry data. To minimise misclassification from data 
entry and handling, data entry was internally audited by 
local teams and data interpretation was reduced to an 
absolute minimum and only performed centrally. Recall 
bias was minimised by the triangulation of different data 
sources and by ensuring that the patients received the 
questionnaire with a limited time window after the cancer 
diagnosis.
The overall response of 31% for the patient survey 
varied between jurisdictions. There were likely differ-
ences in the selection bias in individual jurisdictions; our 
patient sampling strategy will have led to some differ-
ences in the composition of our samples, as some patients 
were included directly from registries, some via PCPs 
and, in Northern Ireland, research nurses checked lists of 
potentially eligible patients to confirm eligibility. We have 
no mechanism to examine the direction of such possible 
selection bias. However, comparison of participating 
patients on a number of variables (including comorbidity, 
self-assessed health, smoking, stage, presenting symptom) 
did not show obvious differences with potential to bias 
our results. We also compared age, sex and stage of cancer 
among participants versus eligible patients and found no 
significant differences. There were different classifica-
tion systems for ethnicity and education across jurisdic-
tions which would lead to biased estimates if included in 
the regression model, even if mapped or harmonised—
hence, they were excluded. There were few respondents 
from minority ethnic groups, limiting the generalisability 
of our findings; further work should target these groups 
as they are likely to have unique characteristics in their 
routes to diagnosis.
Confounding from aspects related to the diagnostic 
route for CRC was diminished by adjusting for age, gender 
and comorbidity. It is possible that there is some residual 
confounding which can bias the results in different direc-
tions. The statistical precision of the study was high as 
we were able to show clinically significant differences of 
1 week in time intervals.
Comparison with other studies
Other studies have examined symptoms and routes to 
diagnosis for patients with CRC—although rarely in more 
than a single setting. A UK study on patients diagnosed 
in 2001–2002 and 2007–2008 reported median diagnostic 
intervals of 100 and 80 days, respectively.37 A Danish study 
showed median diagnostic intervals for CRC of between 
31 and 55 days, depending on the timing of measurement 
in relation to implementation of pathway guidance.38 The 
difference between the present study and the former may 
stem from methodology issues, especially data sources 
(ie, databases vs surveys).
A study in Spain showed a symptom to diagnosis interval 
for CRC of 128 days and symptom to treatment interval of 
155 days—these authors found that nature of symptoms, 
perceived seriousness of symptoms by patients, and place 
of first presentation influenced diagnostic and treatment 
intervals.39 Sampling strategies and survey differences will 
have influenced the results, making it difficult to compare 
these studies; nevertheless, they confirm that our results 
are broadly consistent with previous, single-jurisdiction 
studies.
The pattern of symptoms in ICBP participants was 
similar to other studies.40 CRC is known to be a cancer 
that clinically presents with either ‘alarm’ symptoms or 
more vague symptoms; there is evidence that doctors 
and patients respond less promptly to some symptoms of 
CRC than others—and that this can be influenced by the 
presence of co-morbid conditions.41 However, the minor 
differences in symptom patterns seen in table 4 are insuf-
ficient to explain the between-jurisdiction variation we 
have demonstrated in routes to diagnosis and diagnostic, 
treatment and total intervals.
explaining observed differences between jurisdictions
The variation we see between jurisdictions mostly derives 
from differences in the extent to which healthcare systems 
support expedited CRC diagnosis and treatment; indeed, 
some health system characteristics, such as access and 
patient mobility between healthcare providers, may influ-
ence cancer outcomes—although these factors require 
further exploration.42 In Denmark there have been a 
number of reforms specifically designed to reduce diag-
nostic intervals.43 This study indicates a potential to opti-
mise diagnostic routes for CRC in some jurisdictions. This 
should ideally be in conjunction with screening efforts 
which is gaining traction across many Western countries 
in response to policy and guideline initiatives.44
COnClusIOn
This study demonstrates considerable absolute and rela-
tive differences between jurisdictions in time intervals 
from first symptom until treatment for CRC. These differ-
ences do not demonstrate an obvious relationship with 
existing ICBP survival differences between the jurisdic-
tions. ICBP phase 2 will report survival estimates to 2014, 
at which point it may be possible to explore the rela-
tionship between interval lengths and survival estimates 
in the population. Further work is ongoing to explore 
the outcome of patients included in this ICBP M4 study 
alongside the interval lengths observed.
The median total interval, which varied between 74 
and 136 days, indicates that there is unrealised poten-
tial to optimise pathways for CRC. The main differences 
were found for structural parts of the pathway (eg, those 
not relating to patient behaviours/actions). Further, 
there is a ‘tail’ of patients waiting many months longer 
to start treatment for their cancer which may affect their 
outcomes. While our study highlights important interna-
tional differences in routes to diagnosis, further research 
is needed to understand these differences and eluci-
date the contribution of patient pathway guidance and 
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implementation, and health system structures. Neverthe-
less, the data provide important prompts for jurisdictions 
and suggest considerable room for improvement in some 
areas; they will also serve as a benchmark for measuring 
the effectiveness of future interventions.
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